Cell electrophoresis for diagnostic purposes. I. Diagnostic value of the electrophoretic mobility test (EMT) for the detection of gynaecological malignancies. by Hoffmann, W. et al.
Br. J. Cancer (1981) 43, 588
CELL ELECTROPHORESIS FOR DIAGNOSTIC PURPOSES.
I. DIAGNOSTIC VALUE OF THE ELECTROPHORETIC MOBILITY
TEST (EMT) FOR THE DETECTION OF GYNAECOLOGICAL
MALIGNANCIES
W. HOFFMANN*, W. WERNER*, R. STEINERt AND R. KAUFMANNt
From the *Frauen- und Poliklinik der Universitat GOttingen, Hurmboldtallee 3, D-3400 Gottingen
and the tPhysiologi8che8 Institut, Lehrstuahl fur Klinische Physiologie der Universitdt,
Universitdtsstrasse 1, D-4000 Dusseldorf, W. Germany
Receive(d 9 January 1981 Accepted 9 February 1981
Summary.-Lymphocytes from 278 gynaecological patients (100 controls and 178
patients with a malignant condition) have been investigated for their response to
encephalitogenic factor, cancer basic protein, and KCl extract of adenocarcinoma of
the body of the uterus as "antigens", using tanned sheep erythrocytes ETS as indica-
tor particles in the electrophoretic mobility test (EMT). Electrophoretic mobility
was measured with a Zeiss cytopherometer. The study was split into three test
series producing in the cancer group 66% correct positive test results (34%O false
negatives) and in the control group 83% correct negative results (17% false positives).
Consequently, with the instrumentation used, EMT is, at least in our hands, not
sufficiently reliable for the diagnosis of cancer.
SEVERAL RESEARCH CENTRES have investi-
gated the possibility of using the macro-
phage electrophoretic mobility (MEM)
test of Field & Caspary (1970), or one of
its modifications, as a means of cancer
detection. Field has described various
potential technical problems associated
with the test (Field et al., 1973; Field &
Shenton, 1975), one of them being the
quality of the guinea-pig macrophages
used as indicator cells. However, this
problem seemed to have been circum-
vented by Porzsolt et al. (1975), who
replaced the macrophages by tanned and
sulphosalicylated sheep erythrocytes
(ETS), thereby simplifying and improving
the procedure without impairing its effi-
ciency and clinical reliability. This modi-
fied test was called the electrophoretic
mobility test (EMT). Another source of
concern in the test has been the so-called
antigens. It has been reported that
encephalitogenic factor (EF), which has
been used as an antigenic protein, bears
an immunological relationship to certain
basic proteins of the cell membranes of
solid malignant tumours (cancer basic
protein, CaBP Dickinson et al., 1973;
Carnegie et al., 1973). It seemed possible
that a better diagnostic differentiation of
various types of malignancy might be
achieved using CaBP, but this could not
be confirmed. Muller et al. (1975) replaced
EF or CaBP by a hypermolar KCI
extract of different malignant tumours,
and found that this improved the sensi-
tivity of the test and gave a "tumour-
specific" diagnosis.
Several centres (using EF, CaBP or the
KCI extracts as "antigens") confirmed the
results of MEM (Pritchard et al., 1972,
1973; Preece & Light, 1974; Field, 1976;
Irmscher et al., 1975; Klausch et al., 1975;
Meyer-Rienecker et al., 1975; Jenssen
et al., 1976a,b; Nowak et al., 1976;
Klausch et al., 1977; Light & Preece, 1977;
Muller et al., 1977; Gunther et al., 1978),
MOD-MEM (Pritchard et al., 1976) andEMIT IN CANCER DIAGNOSIS
EMT (Jenssen & Shenton, 1975; Lampert
et al., 1977; Shenton et al., 1977; Douwes
et al., 1978; Dyson & Corbett, 1978;
Tautz et al., 1978; Ritter & Oehme, 1978;
Kreienberg et al., 1979; B6gelspacher
et al., 1980), though the procedures have
not gained universal recognition (see also
Bagshawe, 1973; leading article in Nature,
1973; editorial in Lancet, 1976; Bagshawe,
1977; Moore & Lajtha, 1977; Bagshawe,
1978; Moore, 1978).
The contradictory reports on the valid-
ity of the results obtained with the test
ranged from descriptions of its near-
complete accuracy in the diagnosis of
cancer, to reports of its total inability to
provide reliable or meaningful results.
After a small and at first confirmatory
test series in 1973 (Goldstone et al., 1973),
Lewkonia et al. (1974) failed to find any
correlation between the results of MEM
or MOD-MEM tests and clinical diagnosis.
In addition, Pritchard et al. (1978), who
were the first to confirm Field & Caspary's
original results (Pritchard et al., 1972),
recently published the results of their own
blind study. In their cancer group 4300 of
the results were false negatives and in the
so-called healthy control group 34% were
false positives. Whereas Crozier et al.
(1976), Rahi et al. (1976), Rawlins et al.
(1976), Arvilommi et al. (1977), Chiu
et al. (1977) and Nakajima et al. (1977)
rejected the test because ofits inability to
distinguish between subjects with malig-
nant disease and the controls, others have
criticized the theoretical basis of the test
system (Forrester et al., 1977). Shenton
et al. (1977) found, in a mutual study with
the Rostock team, a positive concordance
of the EMT and MEM results and a
high correlation with clinical diagnosis,
but Harlos & Weiss (1978) failed to do
so; only 23 of the 42 samples analysed
showed agreement between the two
systems.
Because of this confusing situation we
have carried out a detailed evaluation of
the EMT system, particularly its possible
role in the diagnosis of gynaecological
malignancies.
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METHODS
Patients.-Venous blood was obtained from
patients of the Universitats-Frauenklinik
Gottingen. None of the patients with malig-
nant disease (malignancy group) had received
treatment. In all cases the diagnosis was
confirmed histologically.
Lymphocytes.-The blood was taken into a
preservative-free heparin (Novo) one-way
syringe and diluted 1: 1 with Dulbecco's
solution (DBPS, Gibco-Biocult). The lympho-
cytes were separated by centrifugation for
30 min at 400 g on Lymphoprep (Nyegaard)
according to the method of Boyum (1968).
The lymphocytes harvested from the inter-
face were washed twice in DBPS and
resuspended to a final concentration of 107
cells/ml. At the end ofthe isolation procedure
cell viability was assessed by the Trypan-blue
exclusion test. The proportion of T lympho-
cytes was roughly estimated by E rosetting.
Antigens.-The "antigenic" proteins were
prepared according to the literature. The
encephalitogenic factor was partly a gift
from Professor Ax and partly isolated accord-
ing to Dickinson et al. (1973). The cancer
basic protein (CaBP) was prepared by the
same method from a carcinoma of the ovary,
while the 3M KCL extract was obtained from
an adenocarcinoma of the corpus uteri
(KCl-Cu) according to Meltzer et al. (1973)
and Muller et al. (1975).
Indicator cells. Tanned and sulphosalicy-
lated stabilized sheep erythrocytes (ETS)
were purchased from Behring. After several
washings in DBPS, the cell concentration was
finally adjusted to 5 x 107/ml.
Incubation.-From each patient one sample
and one control were prepared. For each
sample 0 7 ml of the lymphocyte suspension
was incubated at 37°C, whilst the control (to)
contained no "antigen", 3 ml of "antigen
solution" in the appropriate concentration
was added to the sample tp. After 4h incuba-
tion, 3 ml of "antigen solution" was added to
the control (to), and 1 ml ofETS solution was
added to to and tp. After 90min incubation
at 23°C, samples were introduced into the
electrophoretic chamber of the cytophero-
meter.
Measuring technique.-Determination of
the electrophoretic mobility ofETS was made
in a Zeiss cytopherometer to which a TV
monitor was attached. Before each series of
measurements the instrument was checked
extremely carefully for any malfunction.
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The percentage of slowing was calculated
using the formula
% migration inhibition= P- x 100 to
where Ip and L. are the harmonic mean
transit times of 15 cells measured over a grid
plate (16 ,um) in each forward and backward
direction. When fp > fo the result was
positive; if the ETS of the control migrated
faster than the patient's sample (tp < to) the
change in mobility was negative (relative
acceleration).
According to the literature values of >5%
slowing were arbitrarily considered as indi-
cating the existence of cancer in the patient
tested, due to the production ofmacrophage-
slowing factor (MSF) by the tumour-sensi-
tized antigen-stimulated lymphocytes. Values
<5% slowing and all negative values
were classified as indicating the absence of
malignancy in the patient.
RESULTS
The blood samples of 278 patients were
examined. In 157 a carcinoma of the
genital tract was histologically confirmed,
21 had carcinoma in situ (cis) or severe
dysplasia (sD) of the cervix uteri. 100
patients with no signs of malignant
disease served as controls. The age range
of the patients in the malignancy group
was 31-78 years (average 53) and in the
control group 24-73 years (average 46).
Neurological degenerative and auto-
immune diseases which are reported as
giving false positive results in the test
(Caspary & Field, 1970) were excluded.
TABLE I.-EMT results of the first series
using EF as "antigen"
Clinical diagnosis
Ca cervix uteri
Ca corpus uteri
Ca ovary
Ca vulva
Total
(Carcinomas)
Carcinoma insitul
severe dysplasia
ofcervix uteri
Postmenopausal
bleeding
Uterusmyoma
Incontinence
Sterilization
Pregnancy
Total
(Controls)
Results of EMT
+
20 7
21 20
12 4
1 1
Concordance
EMT/Clin.
(/)
74
51
75
54 32 63
8 6
1
2
2
3
0
13
8
4
9
8
8 42 84
Three independent series of tests were
performed. In the first (Table I) 150
patients (100 with malignant disease and
50 controls) were tested with EF as
"antigen".
In the second series (Table II) (80
patients; 50 with malignant disease, 30
controls), EF, CaBP andKCl-Cuwere used
as "antigens". InalltestsEFwasagainused
as "antigen". Ifenoughlymphocytes could
be isolated, additional samples were incu-
bated either with CaBP (19 patients) and/
or KCl-Cu (12 patients) as "antigens".
The individual test results of the samples
which were tested with two or more
"antigens" are presented in Table III.
Samples from 48 patients were tested
TABLE II.-EMT results of the second series using EF, CaBP and KCU-Cu as "antigen"
Clinical diagnosis
Ca cervix uteri
Ca corpus uteri
Ca ovary
Ca vulva
Ca breast
Total
Carcinoma in situ/
severe dysplasia
cervix uteri
Controls
Incubated
with EF
Results
+ -
11 5
8 3
2 4
3 2
4 1
Concordance
EMT/Clin.
(%)
Incubated
with CaBP
Results
+ -
3 3
2 2
4 2
2 1
0 0
Concordance
EMT/Clin. (%/)
Incubated
with KCl-Cu
Results
+ -
3 1
5 1
2 0
0 0
0 0
Concordance
EMT/Clin.
(%)
28 15 65 11 8 58 10 2 83
1 6
6 24 80 4 5 56 2 6 75
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TABLE III. Individual tet
samples in the 2nd series
one "antigen" has been a
Clinical diagnosis
Ca cervix uteri
Ca corptus uLteri
Ca ovary
Ca vulva
Code
number
10
30
19
20
32
15
3
,31
4
39
64
67
7
23
45
76
25
55
29
2
58
a]
Concordance
EMT/Clin. (o%)
in the third series. 28
gynaecological carcinoma v
no signofmalignancy (cont
Only KCl-Cu was used as '
sample was examined inc
two investigators wellexpel
Zeiss cytopherometer. Th
nosis was not known to
28 patients suffering fror
gynaecological tumour,
reported 17 positive and 1
results, the correspondir
investigator B being 21 ar
TABLE IV.-
st results of the in only 20 of the 28 samples did both
where more than investigators report the same qualitative
sed result (15 both positive and 5 both
Results with EMT negative), thus precluding a mutual eval-
fterincubationwith uation in 8 cases. Therefore, these 8
EF CaBPKCI-Cu samples were re-examined in the cyto-
+ + + pherometer by both investigators, giving
+ + + then 6 positive and 2 negative unanimous
+ - + test results by both investigators. Thus,
+ + 21 tests could be defined finally by both
+ - investigators as positive and 7 as negative.
+ + + In the 20 patients used as controls, 17
+ _ + cases were classified as test-negative
+ _ _ and 3 as positive (included in the 17
- + are 5 classified as negative only after re-
+- + + testing).
+ + + In the third series, from 6 of the 13
- + patients with an adenocarcinoma of the
- _ corpus uteri a double amount of blood
could be extracted, enabling duplicate
+ + testing (Table V). The samples were
+ arranged in such a way that neither of the
- + investigators knew the diagnosis, nor
62 58 83 which samples were duplicates. Indepen-
dently of each other, the investigators
patients had a found corresponding results in 6 of the
while 20 showed 12 tested samples (Pts A, B, C), 4 of
rols) (TableIV). which were classified as positive (Pts A
'antigen". Each and B), 2 as negative (Pt C) (Table V).
lependently by The test result of 2 samples (Pts D and E)
riencedwith the were positive whereas their duplicates
e clinical diag- were negative. In one patient (F) both
them. In the investigators found a negative and in the
n a malignant duplicate a positive result. Re-testing
investigator A became necessary in 5 cases, since the two
L1 negative test investigators obtained discrepant results.
ng figures for Three samples were finally classified as
nd 7. However, positive, two as negative.
-EMT results of the 3rd series using KCl-Cu as "antigen" independently
measured by 2 investigators (A and B)
Clinical diagnosis
Ca cervix uteri
Ca corpus uteri
Ca ovary
Ca vulva
Total (carcinomas)
Controls
Results of EMT
(first testing)
+_
A B A B
6 7 3 2
8 10 5 3
1 2 3 2
2 2 0 0
17 21 11 7
4 7 16 1:
Final results of EMT
(after retesting)
+_
7
10
2
21 (750%)
3 (15%)
2
3
2
0
7 (25 %)
17 (85%)
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TABLE V.-EMT results of duplicate samples of 6 patients (clinical diagnosis: adeno-
carcinoma corpus uteri) from the 3rd series (2 examiners, A and B)
Code number First results
A A
Sample Duplicate
32
42
6
16
52
45
40
43
14
19
54
49
A
+
Retesting
(on failure of
B A & B to agree) Final result
+
yes
yes
yes
yes
yes
+
+
+
+
TABLE VI. Classification of
according to the clinical
carcinoma
Clinical diagnosis
Carcinoma in situl
severe dysplasia
cervix uteri
Ca cervix uteri
Stage I
II
III
IV
Ca corpus uteri
Stage I
II
III
IV
EMT
+_
EMT results
stage of the
Concordance
EMT/Clin.
(0)
9 12
38
18
10
9
1
39
23
3
11
2
14
4
6
2
2
26
18
5
3
0
73
82
63
82
33
60
56
38
79
100
DISCUSSION
After the introduction of the MEM test
in 1970, a number of independent groups
have published reports sometimes with an
astonishing amount of agreement between
the test results and the clinical diagnosis,
thus confirming Field and Caspary's
proposal that the test is a valuable tool
for cancer diagnosis. Nevertheless, neither
the MEM nor its simplified and allegedly
equally efficient modifications (MOD-
MEM, EMT) gained widespread recogni-
tion as a practicable cancer test, and
dispute about the quality and value of
this test system in providing immuno-
logical evidence for malignant tumours is
still unresolved. This caused us to carry
out our own testing with blood samples
from 278 patients using the three "anti-
genic" proteins, EF, CaBP and KCl-Cu,
described in literature.
In the first series, with 150 patients,
only EF was used as "antigen". In the
second series, CaBP and KCl-Cu were also
applied in 80 patients. In the third series
48 patients were tested exclusively with
KCl-Cu. After the incubation procedure
the samples of the third series were
evaluated independently by two investi-
gators and the extent of slowing or
acceleration was recorded separately.
Without the investigators' knowledge,
duplicate samples from 6 patients with
adenocarcinoma of the corpus uteri were
introduced into the third series.
Although precancerous stages like cis/
sD of the cervix cannot be classified as
malignant, they are, as a subgroup, listed
among the carcinomas in this investigation
since MEM as well as EMT results are
reported to be predominantly positive
(Porzsolt et al., 1975; Klausch et al., 1975;
Bogelspacher et al., 1980). According to
these authors, this proves the sensitivity
of the test, for, they allege, the test was
able to detect even the minute changes
caused by precancerous diseases. Of the
21 precancerous cases examined by us,
9 showed the positive result expected for
malignancy; in 12 the result was negative.
Pt.
A
B
C
D
E
F
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Therefore, at least in our hands, EMT
gave no clear-cut answer and was of no
diagnostic help.
In examining patients with proven
malignant tumours the best rate we could
achieve was 75%0 agreement between the
test results and the clinical diagnoses
(3rd series). Taken together, the 3 series
averaged 63% correlation between EMT
and clinical diagnosis. Excluding the cases
with cis/sD, the average was 66%. In 37%0
of the tested patients the result was
negative despite the presence of histo-
logically proven malignancy (without the
cis/sD cases: 34%0).
In the first series, in which 86 patients
with confirmed malignancy were tested
with EF as "antigen", only 63% positive
and 37% negative results were obtained.
The worst accuracy was obtained in
patients with carcinoma of the corpus
uteri; in only 51% did the test correlate
with the clinical diagnosis.
In order to improve on these disappoint-
ing results, in the second series we tried to
apply more specific "antigens". Lympho-
cytes from 19 ofthese cancer patients were
stimulated in addition to EF with CaBP,
and from 12 with KCl-Cu as "antigenic
proteins". With 65%0 positive tests, the
results with EF just about equalled those
of the first series, whilst the substitution
of CaBP as antigen achieved only 58%
positive results (Table II).
If we correlate the results of the EF
incubation with those of the CaBP
incubation, without taking into account
the clinical diagnosis, it is striking that in
8 cases (42%) the test result differed
according to "antigen", EF or CaBP, was
applied. Three times the test with CaBP
was positive (correct), but negative (false)
in the EF system; 5 times vice versa
(Table III).
In the 12 samples incubated with KCI-
Cu the result was correct (i.e. positive)
10 times (83%). However, if we correlate
these results with the results ofincubation
with the other two antigens of samples
from the same patients, we receive
corresponding results in only 7 cases
(58%) compared with EF incubation and
in 8 cases (67%) compared with CaBP
incubation. Of 10 samples incubated
with all 3 antigens, only 6 showed 3
correct results; 4 gave a different result
in one system from that with the other
two.
The more favourable results obtained
with KCl-Cu could only be regarded as
tentative owing to the small number of
samples tested. Therefore, in the 3rd series
only KCl-Cu was used. Also, after incuba-
tion the samples were evaluated in the
cytopherometer independently by two
investigators. In their first evaluation
they unanimously declared only 15/28
samples ofthe carcinoma group as positive
(58%). Re-testing of 8 samples, which had
at first been analysed differently by the
two investigators, produced another 6
positive evaluations: a total of 21 positive
cases (Table IV). In this way, 75% of the
cases the test results could finally be
declared positive, and in accordance with
the clinical diagnosis of cancer. However,
only 13/28 patients suffered from car-
cinoma of the corpus uteri. Of these 13,
10 (77%) were correctly identified by
both investigators (3 re-testings had been
necessary). But a positive EMT result
was also obtained in 7/9 patients with
squamous carcinoma of the cervix, in 2/4
with a carcinoma of the ovaries and in 2
with a carcinoma of the vulva. These
results are surprising, in that according to
the publications of Muller et al. (1975)
application of "organ-specific" KCI-Cu
should cause only lymphocytes ofpatients
with an adenocarcinoma of the corpus
uteri to react by the production of MSF,
i.e. the "specific response oflymphokines".
According to these authors, lymphocytes
from all patients with cancer in a different
location or with no cancer at all (controls)
ought to show no reaction whatsoever
(negative results).
In the 3rd series we also introduced
duplicate samples from 6 of the 13
patients with corpus carcinoma without
the knowledge of the investigators (Table
V). In 3 patients, duplicate samples were
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analysed by both investigators, but only
in 2 of these did the test result correspond
to the clinical diagnosis. In one case, both
investigators arrived at a false-negative
result in the duplicate samples of the
same patient. In the remaining 3 patients
duplicate samples yielded different results.
At first sight, Table IV might suggest
that Investigator B's results more often
agreed with the clinical diagnosis than
those of Investigator A. However, if we
add the results shown in Table V we
arrive at a correct quote of 8 for Investi-
gator A compared to only 5 for Investiga-
tor B (16 mutually tested samples).
Moreover, Investigator B shows a higher
rate of false positive values (controls in
Table IV); i.e. 7 compared to 4 by
Investigator A in 20 control tests. Both
investigators thus seem to be equally
skilled in handling the system.
It is conceivable that in advanced
cancer the immunological reactivity of
the organism is exhausted and that the
respective lymphocytes are therefore not
"marked" any more, making them un-
detectable in the test system, the results
of which would remain negative despite
the clinical diagnosis of cancer (Field,
1973). It is also possible that with growing
numbers of malignant cells (growing
tumour mass) an increased number of
sensitized mononuclear cells are bound to
the tumour itself, thus reducing their
number in the periphery and their avail-
ability for testing (sponge phenomenon,
Field & Caspary, 1972). If one of these
theoretical considerations were the cause
of the poor correlation between the test
results and the clinical diagnosis in our
investigation, one would expect the rate
of correct test results to vary with the
size or stage of the tumour. That is why
the results of all 3 series were tabulated
for cis/sD and for the stages of the portio
and the carcinoma of the body of the
uterus in groups according to the clinical
stage (Table VI). It shows varying
percentages of correct results within the
difference groups, but their correlation to
the stage of the carcinoma seems random.
TABLE VII.-EMT results of all 3 test
series (+ /-)
Clinical diagnosis
Ca cervix uteri
Ca corpus uteri
Ca ovary
Ca vulva
Ca breast
Total (carcinomas)
Concordance ( %)
Carcinoma in situ/
severe dysplasia
cervix uteri
Postmenopausal
bleeding
Uterusmyoma
Incontinence
Sterilization
Pregnancy
Benign ovarian tLumours
Adnexitis
Total (controls)
Concor(lance (o%)
Series
I II III
20/7 11/5 7/2
21/20 8/3 10/3
12/4 2/4 2/2
1/1 3/2 2/0
0/0 4/1 0/0
54/32 28/15 21/7
63 65 75
8/6 1/6 0/0
1/13
2/8
2/4
3/9
0/8
0/0
0/0
8/42
84
1/4
0/2
1/5
2/7
0/,3
2/3
0/0
6/24
80
2/6
0/2
0/0
0/0
1/4
0/0
0/5
3/17
85
Total
38/14
39/26
16/10
6/3
4/1
103/54
66
9/12
4/23
2/12
319 5/16
1/15
2/3
0/5
17/83
83
Negative results were established with
the EMT in 83%o of the 100 patients who
served as controls and were hospitalized
for non-malignant diseases. This rate
differed between 80 and 85% within the
single series (Table VII). Interpretation of
the so-called false positive values is
difficult unless we assume complete in-
effectiveness of the test system. Although
no malignant disease had been detected in
these patients, the existence of an occult
or micro-carcinoma undetected to this
moment cannot be excluded with certainty
for every single case; it is conceivable that
MEM/EMT tests give accurate positive
results at a very early stage in the develop-
ment ofthe cancer, long before there is any
clinical manifestation of the cancer. How-
ever, a 15-20% rate seems too high for
this assumption.
A compilation of the individual results
of all 3 series is shown in the Figure, in
which the percentages of slowing and
acceleration are shown graphically. From
the second series only the results with EF
are considered. An acceptable "discrim-
ination line" to distinguish between
malignant (cancer) and non-malignant
disease is not recognizable.
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Diagnosis Acceleration Inhibition
-20 -10 0 +10 +20
Ca cervix uteri * * *'* 0
0 0o* *. 0 so @0a
Ca corpus uteri l * * * 0 *
Ca ovary * . .
Ca vulva . a. .
Ca mamma
carcinoma in situ . *
Climact. hemorrhage .
S ~~~~0 0 ~0 0
Uterusmyoma . .
0 0 00 0 0
Incontinence . .
Sterilization . . * *I * *
Pregnancy . . .
Benign ovarian tu. I .
Adnexitis . .
FIG. Individual results of acceleration and inhibition in EMT of the 3 series. Dashed line: arbitrary lower
limit of "positives".
CONCLUSION
Critical and comparative evaluation of
the results of the tests with the three
"antigens" (Table II), as well as the
analyses of the individual results obtained
by the two investigators (Table III),
suggest poor reproducibility of the EMT
procedure in general. The system has at
least three weaknesses:
(1) the ihdicator particles
(2) the so-called "antigens"
(3) the handling of the cytopherometer.
The call for simplification of the indi-
cator cells seemed to have been satisfied
with the introduction ofthe ETS. Whether
we are dealing here with the same reactive
mechanism for the "cellular immune
reaction" as when using macrophages is
still to be seen.
From an immunological point of view
the "antigenic" preparations are crude
extracts containing a number of different
proteins. If the test really works on ani
immunological basis these extracts should
be purified. The first question is, however,
whether the fundamental part of the test
procedure handling of the cytophero-
meter is capable of supplying repro-
ducible and reliable results. The perform-
ance of this instrument, as well as the
personal skill in handling, seem to be
decisive for the test procedure. Since this
is a precondition for any improvement-
be it isolation ofpurified and more defined
antigens or development of new indicator
cells its value for the MEM, MOD-MEM
or EMT, can only be estimated by means
of a reliable method of cytopherometry.
It was thus our primary task to evaluate
the physical possibilities and technical
limitations of the Zeiss cytopherometer,
which is used by most investigators
working with the EMT-MEM or MOD-
MEM tests. These results are presented in
the following paper.
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